Abstract：
Attention deficit hyperactivity disorder (ADHD) is a neurological condition frequently identified in early childhood and frequently co-occurs with other neuropsychological disorders, particularly autism. Viloxazine hydrochloride, a non-stimulant medication, has recently gained approval for treating attention-deficit hyperactivity disorder. This paper describes the first spectrofluorimetric method for precisely measuring the content of viloxazine in pharmaceutical capsules and rat plasma. This method employed NBD-Cl (4-chloro-7-nitrobenzo-2-oxa-1,3-diazole) as a fluorescent probe, which transformed viloxazine in an alkaline environment into a remarkably sensitive fluorescent adduct. Upon excitation at 476 nm, this adduct becomes detectable at a wavelength of 536 nm. The method was validated using ICH criteria, revealing acceptable linearity across a concentration range of 200-2000 ng/ml and high sensitivity with LOD and LOQ values of 46.774 ng/ml and 141.741 ng/ml, respectively. This method was adeptly applied in a pharmacokinetic study of viloxazine in rat plasma following a single oral dose (10 mg/kg), yielding a mean peak plasma concentration (Cmax) of 1721 ng/ml, achieved within 1.5 h. Furthermore, the environmental impact of the technique was assessed using two greenness assessment tools, revealing a notable level of eco-friendliness and sustainability.
摘要：
注意缺陷多动障碍（ADHD）是一种神经系统疾病，经常在儿童早期发现，并经常与其他神经心理疾病同时发生。特别是自闭症。盐酸维洛嗪，一种非兴奋剂药物,最近获得了治疗注意力缺陷多动障碍的批准。本文介绍了第一种精确测量药物胶囊和大鼠血浆中维洛嗪含量的荧光光谱法。该方法使用NBD-Cl（4-氯-7-硝基苯并-2-氧杂-1,3-二唑）作为荧光探针，它在碱性环境中将维洛嗪转化为非常敏感的荧光加合物。在476nm激发时，该加合物在波长536nm处变得可检测到。该方法使用ICH标准进行了验证，揭示了在200-2000ng/ml浓度范围内可接受的线性和高灵敏度，LOD和LOQ值为46.774ng/ml和141.741ng/ml，分别。此方法适用于单次口服剂量（10mg/kg）后大鼠血浆中维洛嗪的药代动力学研究，产生1721ng/ml的平均血浆峰值浓度（Cmax），在1.5小时内实现。此外，使用两种绿色度评估工具评估了该技术对环境的影响，揭示了显著的生态友好性和可持续性。
